Geburtshilfe Frauenheilkd 2019; 79(06): e14
DOI: 10.1055/s-0039-1692077
Abstracts
Georg Thieme Verlag KG Stuttgart · New York

Therapy of ovarian cancer (OC) in Germany – Treatment characteristics QS OVAR 2016

IB Runnebaum
1   Klinik und Poliklinik für Frauenheilkunde und Fortpflanzungsmedizin, Universitätsklinikum Jena
,
F Hilpert
2   Onkologisches Therapiezentrum Krankenhaus Jerusalem, Hamburg
,
A du Bois
3   Klinik für Gynäkologie & Gyn. Onkologie, Kliniken Essen-Mitte, Essen
,
P Harter
3   Klinik für Gynäkologie & Gyn. Onkologie, Kliniken Essen-Mitte, Essen
› Author Affiliations
Further Information

Publication History

Publication Date:
22 May 2019 (online)

Also available at
 

Introduction:

Quality of treatment in patients with OC is one of the main prognostic factors. The Qualitätssicherung Ovar (QS Ovar) was implemented as a nationwide initiative in 2000 in Germany and repeated about every 4 years.

Methods:

All hospitals in Germany were asked to document their patients anonymously with first diagnosis of OC in Q3/2016.

Results:

267 hospitals documented 940 pts (> 60% of all pts in Germany). Surgical staging according to guidelines was done in 69.6% of patients with early OC (FIGO I-IIA). There was a significant improvement (p < 0.001) compared to earlier years (e.g. 38.8% in 2004). Missing procedures were e.g. peritoneal biopsies (27.1%) and para-aortic lymphadenectomy (25.2%). 78.5% received the standard chemotherapy. 4-year overall survival (OS) in patients with standard therapy was 92.0% vs. 78.5% in patients not treated according to guidelines (p = 0.003). 77.2% were diagnosed at advanced FIGO stage IIB-IV. The rate of complete resection was 44.5%, which has also improved compared to earlier years (p = 0.004). 90.8% of the patients treated with chemotherapy received the recommended standard of at least carboplatin and paclitaxel and 64.6% received in addition bevacizumab.

Conclusion:

The quality of treatment has improved. In surgical staging of early ovarian cancer is still room for improvement. Survival follow up is ongoing and should show if optimization of baseline treatment also improves prognosis.